Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7554/eLife.66125 http://scihub22266oqcxt.onion/10.7554/eLife.66125 33682678!8034977!33682678     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33682678&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Elife 2021 ; 10 (ä): ä Nephropedia Template TP {{tp|p=33682678|t=2021. An open label trial of anakinra to prevent respiratory failure in COVID-19 |pdf=|usr=}}{{33682678}} gab.com Text An open label trial of anakinra to prevent respiratory failure in COVID-19 JO: Elife http://www.kidney.de/pget.php?&tw=1&pmid=33682678 #FOAvip BACKGROUND: It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. METHODS: A total of 130 patients with suPAR >/=6 ng/ml were assigned to subcutaneous anakinra 100 mg once daily for 10 days. Primary outcome was SRF incidence by day 14 defined as any respiratory ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes were 30-day mortality and inflammatory mediators; 28-day WHO-CPS was explored. Propensity-matched standard-of care comparators were studied. RESULTS: 22.3% with anakinra treatment and 59.2% comparators (hazard ratio, 0.30; 95% CI, 0.20-0.46) progressed into SRF; 30-day mortality was 11.5% and 22.3% respectively (hazard ratio 0.49; 95% CI 0.25-0.97). Anakinra was associated with decrease in circulating interleukin (IL)-6, sCD163 and sIL2-R; IL-10/IL-6 ratio on day 7 was inversely associated with SOFA score; patients were allocated to less severe WHO-CPS strata. CONCLUSIONS: Early suPAR-guided anakinra decreased SRF and restored the pro-/anti-inflammatory balance. FUNDING: This study was funded by the Hellenic Institute for the Study of Sepsis, Technomar Shipping Inc, Swedish Orphan Biovitrum, and the Horizon 2020 Framework Programme. CLINICAL TRIAL NUMBER: NCT04357366. Twit Text FOAVip An open label trial of anakinra to prevent respiratory failure in COVID-19 ????Elife http://www.kidney.de/pget.php?&tw=1&pmid=33682678 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33682678 #FOAvip English Wikipedia <ref>{{Cite pmid|33682678}}</ref> An open label trial of anakinra to prevent respiratory failure in COVID-19 #MMPMID33682678 Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ Elife 2021[Mar]; 10 (ä): ä PMID33682678show ga BACKGROUND: It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. METHODS: A total of 130 patients with suPAR >/=6 ng/ml were assigned to subcutaneous anakinra 100 mg once daily for 10 days. Primary outcome was SRF incidence by day 14 defined as any respiratory ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes were 30-day mortality and inflammatory mediators; 28-day WHO-CPS was explored. Propensity-matched standard-of care comparators were studied. RESULTS: 22.3% with anakinra treatment and 59.2% comparators (hazard ratio, 0.30; 95% CI, 0.20-0.46) progressed into SRF; 30-day mortality was 11.5% and 22.3% respectively (hazard ratio 0.49; 95% CI 0.25-0.97). Anakinra was associated with decrease in circulating interleukin (IL)-6, sCD163 and sIL2-R; IL-10/IL-6 ratio on day 7 was inversely associated with SOFA score; patients were allocated to less severe WHO-CPS strata. CONCLUSIONS: Early suPAR-guided anakinra decreased SRF and restored the pro-/anti-inflammatory balance. FUNDING: This study was funded by the Hellenic Institute for the Study of Sepsis, Technomar Shipping Inc, Swedish Orphan Biovitrum, and the Horizon 2020 Framework Programme. CLINICAL TRIAL NUMBER: NCT04357366. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Anti-Inflammatory Agents/*administration & dosage[MESH] |Antigens, CD/blood[MESH] |Antigens, Differentiation, Myelomonocytic/blood[MESH] |COVID-19/mortality[MESH] |Female[MESH] |Humans[MESH] |Incidence[MESH] |Injections, Subcutaneous[MESH] |Interleukin 1 Receptor Antagonist Protein/*administration & dosage[MESH] |Interleukin-10/blood[MESH] |Interleukin-6/blood[MESH] |Male[MESH] |Middle Aged[MESH] |Receptors, Cell Surface/blood[MESH] |Receptors, Urokinase Plasminogen Activator/blood/metabolism[MESH] |Respiration, Artificial[MESH] |Respiratory Insufficiency/epidemiology/*prevention & control[MESH] |SARS-CoV-2[MESH] |Standard of Care[MESH]An open label trial of anakinra to prevent respiratory failure in COVI(epmc).pdf DeepDyve Pubget Overpricing